Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan

被引:76
|
作者
Khan, MA
Walley, JD
Witter, SN [1 ]
Imran, A
Safdar, N
机构
[1] Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England
[2] Assoc Social Dev, Islamabad, Pakistan
[3] Univ Leeds, Nuffield Inst Hlth, Leeds LS2 9JT, W Yorkshire, England
[4] USAID Off, Islamabad, Pakistan
关键词
DOT; tuberculosis; direct observation; patient compliance; costing study; cost-effectiveness analysis; Pakistan;
D O I
10.1093/heapol/17.2.178
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
An economic study was conducted alongside a clinical trial at three sites in Pakistan to establish the costs and effectiveness of different strategies for implementing directly observed treatment (DOT) for tuberculosis. Patients were randomly allocated to one of three arms: DOTS with direct observation by health workers (at health centres or by community health workers); DOTS with direct observation by family members; and DOTS without direct observation. The clinical trial found no statistically significant difference in cure rate for the different arms. The economic study collected data on the full range of health service costs and patient costs of the different treatment arms. Data were also disaggregated by gender, rural and urban patients, by treatment site and by economic categories, to investigate the costs of the different strategies, their cost-effectiveness and the impact that they might have on patient compliance with treatment. The study found that direct observation by health centre-based health workers was the least cost-effective of the strategies tested (US$310 per case cured). This is an interesting result, as this is the model recommended by the World Health Organization and International Union against Tuberculosis and Lung Disease. Attending health centres daily during the first 2 months generated high patient costs (direct and in terms of time lost), yet cure rates for this group fell below those of the non-observed group (58%, compared with 62%). One factor suggested by this study is that the high costs of attending may be deterring patients, and in particular, economically active patients who have most to lose from the time taken by direct observation. Without stronger evidence of benefits, it is hard to justify the costs to health services and patients that this type of direct observation imposes. The self-administered group came out as most cost-effective ($164 per case cured). The community health worker sub-group achieved the highest cure rates (67%), with a cost per case only slightly higher than the self-administered group ($172 per case cured). This approach should be investigated further, along with other approaches to improving patient compliance.
引用
收藏
页码:178 / 186
页数:9
相关论文
共 50 条
  • [31] Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
    Haukaas, Fredrik Salvesen
    Arnesen, Trude Margrete
    Winje, Brita Askeland
    Aas, Eline
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (04): : 405 - 415
  • [32] Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis
    Fredrik Salvesen Haukaas
    Trude Margrete Arnesen
    Brita Askeland Winje
    Eline Aas
    The European Journal of Health Economics, 2017, 18 : 405 - 415
  • [33] Cost-effectiveness of two endovascular treatment strategies vs intravenous thrombolysis
    Bouvy, J. C.
    Fransen, P. S. S.
    Baeten, S. A.
    Koopmanschap, M. A.
    Niessen, L. W.
    Dippel, D. W. J.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (05): : 351 - 359
  • [34] Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
    Rens, Neil E.
    Uyl-de Groot, Carin A.
    Goldhaber-Fiebert, Jeremy D.
    Croda, Julio
    Andrews, Jason R.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (12) : 3136 - 3143
  • [35] UNIVERSAL PUBLIC FINANCE OF TUBERCULOSIS TREATMENT IN INDIA: AN EXTENDED COST-EFFECTIVENESS ANALYSIS
    Verguet, Stephane
    Laxminarayan, Ramanan
    Jamison, Dean T.
    HEALTH ECONOMICS, 2015, 24 (03) : 318 - 332
  • [36] Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis
    Diel, R.
    Wrighton-Smith, P.
    Zellweger, J-P.
    EUROPEAN RESPIRATORY JOURNAL, 2007, 30 (02) : 321 - 332
  • [37] Accounting for future costs in medical cost-effectiveness analysis
    Meltzer, D
    JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) : 33 - 64
  • [38] Future costs in cost-effectiveness analysis: an empirical assessment
    Kruse, Marie
    Sorensen, Jan
    Gyrd-Hansen, Dorte
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (01): : 63 - 70
  • [39] Future costs in cost-effectiveness analysis: an empirical assessment
    Marie Kruse
    Jan Sørensen
    Dorte Gyrd-Hansen
    The European Journal of Health Economics, 2012, 13 : 63 - 70
  • [40] The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities
    Dieynaba S. N’Diaye
    Ntwali Placide Nsengiyumva
    Aashna Uppal
    Olivia Oxlade
    Gonzalo G. Alvarez
    Kevin Schwartzman
    BMC Medicine, 17